In advanced NSCLC patients, increased expression of CD8+ TILs detected by IHC or CD8A mRNA transcripts was associated with prolonged PFS treatment with PD-L1 inhibitors, especially in combination with PD-L1 mRNA and protein expression, suggesting that integrated biomarkers may provide higher predictive value (71). This evidence concerns the gene CD8A and non-small cell lung carcinoma.